Vaishali Pharma’s Q3 FY24 marked by a remarkable 37.59% increase in revenue

Q3 FY24

– Total Income at ₹ 28.37 Cr

– EBITDA at ₹ 3.42 Cr

– EBITDA Margin at 12.05%

– Net Profit at ₹ 2.11 Cr

– NPM (%) at 7.44%

– EPS at ₹ 1.99

9M FY24

– Total Income at ₹ 55.01 Cr

– EBITDA at ₹ 9.05 Cr

– EBITDA Margin at 16.45%

– Net Profit at ₹ 5.4 Cr

– NPM (%) at 9.82%

– EPS at ₹ 5.10

Commenting on the performance, Atul Vasani, Chairman and Managing Director of Vaishali Pharma Limited said, “We are delighted to share our Q3 FY24 results, reflecting our steadfast commitment to innovation, high-quality standards, and strategic global expansion through valuable partnerships. Notably, we introduced our latest brand, “HealthE,” through an online platform, showcasing our dedication to providing health and wellness solutions that enhance lives. Additionally, our participation in CPHI Barcelona (Spain) underscores our active engagement in the global market. Our ongoing collaborations and strategic ventures, including the Nutraceutical Products segment, position us for future growth.

We look forward to advancing our journey towards excellence, prioritizing stakeholder value and contributing significantly to global healthcare improvement.”

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.